Celanese lands Gates Foundation grant for refillable contraceptive research

By Jenni Spinner

- Last updated on GMT

(Inna Miller/iStock via Getty Images Plus)
(Inna Miller/iStock via Getty Images Plus)

Related tags Gates Foundation contraceptives birth control Drug delivery systems R&D Drug delivery technology

The company has landed funding from the Bill and Melinda Gates Foundation for research and development on a prototype of a refillable contraceptive solution.

Global chemical and specialty materials company Celanese has announced the receipt of a grant from the Bill and Melinda Gates Foundation to produce and characterize a working prototype for a refillable contraceptive implant. According to the company, the research and development will be conducted within the Celanese Pharmaceutical Development and Feasibility Lab, and the project is expected to produce a functional prototype that meets all established project parameters within an 18-month timeframe.

The development of a refillable contraceptive implant has the potential to benefit women in low- and middle-income countries who currently either do not have access to modern contraceptive options or could benefit from the flexibility and control of the contraception this product design affords. Through this grant, Celanese will be providing critical research and development activities intended to facilitate and accelerate access to long-acting contraceptive options.

Laura Brand, VP of medical and pharmaceutical business, Celanese

We have a long history working in the area of women’s health and are honored by the trust placed in our team through this grant from the Gates Foundation​,” said Laura Brand, vice president of the Celanese medical and pharmaceutical business. “The project concept is based on our VitalDose drug delivery platform, a controlled release technology with decades of commercial use in the US and Europe​.”

We are proud to be part of this opportunity to expand access to solutions for women’s health to many more women globally​,” Brand added.

Celanese provides a range of medical and pharmaceutical material solutions and development support to pharmaceutical and medical device companies worldwide. With more than 40 years of experience supporting key applications and the demanding requirements of healthcare, Celanese continues to invest in this area, including by finding new ways to deliver a sustained dose of medication over time.

According to Celanese, the company’s expanding portfolio includes solutions and technologies for applications across drug delivery, medical devices, orthopedics, advanced surgical instruments, and connected devices. 

Related news

Related products

show more

How a Clinical MDR Helps with Data Quality

How a Clinical MDR Helps with Data Quality

Formedix | 16-Jan-2023 | Technical / White Paper

This article covers the many ways a clinical metadata repository helps with data quality in the clinical trial process, and how it ultimately helps to...

Optimizing Adherence in DCTs

Optimizing Adherence in DCTs

PPD - Decentralized Clinical Trials | 12-Jan-2023 | Technical / White Paper

Prioritizing greater patient-centricity and creating an opportunity to reach unprecedented patient groups, decentralized and hybrid clinical trials are...

PPD is Supporting Complex EU DCTs

PPD is Supporting Complex EU DCTs

PPD - Decentralized Clinical Trials | 05-Jan-2023 | Technical / White Paper

PPD supports European DCTs and clinical trial sponsors with a holistic and comprehensive approach

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 14-Dec-2022 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Related suppliers

Follow us


View more